NFKB1 and psoriasis: In fact, our study found that all biologics for psoriasis under R&D in the clinical trial stage by these local pharmaceutical companies were biosimilars or “me-too” drugs, when the global psoriasis pipeline has broadened to novel targets, such as ICAM1, NF-kB, REV3 L, ADRA1B, and CCL11 (Bui, et al., 2021).